S. Korea begins review of Pfizer's oral COVID-19 pill_老虎社区_美港股上老虎

S. Korea begins review of Pfizer's oral COVID-19 pill

Yonhap2021-12-22

SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19. Paxlovid...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

soosoo
·2021-12-22
Good sharing
回复
5
举报
收起
- dnhos0005:
  ok
  2021-12-22
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1188384720?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-22 14:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188384720","market":"us","top_or_hot":-1,"title":"S. Korea begins review of Pfizer's oral COVID-19 pill","media":"Yonhap","content":"<div>\n<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.\nPaxlovid...</p>\n\n<a href=\"https://en.yna.co.kr/view/AEN20211222004300320?section=search\">网页链接</a>\n\n</div>\n","source":"lsy1640152899971","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S. Korea begins review of Pfizer's oral COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS. Korea begins review of Pfizer's oral COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 14:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://en.yna.co.kr/view/AEN20211222004300320?section=search><strong>Yonhap</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.\nPaxlovid...</p>\n\n<a href=\"https://en.yna.co.kr/view/AEN20211222004300320?section=search\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://en.yna.co.kr/view/AEN20211222004300320?section=search","article_id":"1188384720","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188384720","pubTimestamp":1640152952,"columns":[],"sourceInfo":{"source_id":"lsy1640152899971","name":"Yonhap"},"weMediaInfo":null,"summary":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewi","collect":0,"end_time":0,"defaultTopTitle":"yna.co.kr","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"韩国开始审查辉瑞口服新冠肺炎药丸","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.\nPaxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.\nThe Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)\nIf authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.\nThe drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.\nThe U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.\nPfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":691125672,"gmtCreate":1640153102058,"gmtModify":1640153102425,"author":{"id":"4089777453696550","authorId":"4089777453696550","name":"soosoo","avatar":"https://static.tigerbbs.com/a7a8e4a0c1e8d4b7bf1e9db91cfaffc8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4089777453696550","authorIdStr":"4089777453696550"},"htmlText":"Good sharing","listText":"Good sharing","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691125672","repostId":1188384720,"repostType":4,"repost":{"id":"1188384720","kind":"news","pubTimestamp":1640152952,"share":"https://www.laohu8.com/m/news/1188384720?lang=&edition=full","pubTime":"2021-12-22 14:02","market":"us","language":"en","title":"S. Korea begins review of Pfizer's oral COVID-19 pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1188384720","media":"Yonhap","summary":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewi","content":"<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.</p>\n<p>Paxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f5435876a060de363e87a33887064854\" tg-width=\"500\" tg-height=\"324\" width=\"100%\" height=\"auto\"><span>The Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)</span></p>\n<p>If authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.</p>\n<p>The drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.</p>\n<p>The U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck &amp; Co.'s pill this week, according to multiple media reports.</p>\n<p>Pfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.</p>","source":"lsy1640152899971","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S. Korea begins review of Pfizer's oral COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS. Korea begins review of Pfizer's oral COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 14:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://en.yna.co.kr/view/AEN20211222004300320?section=search><strong>Yonhap</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.\nPaxlovid...</p>\n\n<a href=\"https://en.yna.co.kr/view/AEN20211222004300320?section=search\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://en.yna.co.kr/view/AEN20211222004300320?section=search","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188384720","content_text":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.\nPaxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.\nThe Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)\nIf authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.\nThe drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.\nThe U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.\nPfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7075161,"gmtCreate":1640155696046,"gmtModify":1640155696145,"authorId":3571777241907892,"author":{"id":3571777241907892,"idStr":"3571777241907892","authorId":3571777241907892,"name":"dnhos0005","avatar":"https://static.tigerbbs.com/1620be42110eb49d6fefba05ef25ab29","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":691125672,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":22,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}